arrow
J

Jürgen Finke

University of Gottingen
H指数:87
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

纠正:基于体内T细胞清除(ATG与alemtuzumab)的GVHD预防方案比较,用于接受异基因造血干细胞移植的AML患者,移植预处理强度为中等强度方案:代表EBMT急性白血病工作组进行的登记研究

2026-10-230
OAAI
Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

基于体内T细胞清除(ATG与alemtuzumab)的GVHD预防方案比较:在异基因无关供者移植且采用中间强度预处理方案的患者中治疗AML的登记研究——代表EBMT急性白血病工作组

2026-09-100
OAAI
Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation

TP53突变特征及异基因造血细胞移植后急性髓系白血病的结局分析

2026-09-040
OA
Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT)

自体造血干细胞移植治疗自身免疫性疾病的晚期并发症:欧洲血液与骨髓移植学会(EBMT)自身免疫性疾病工作组(ADWP)、移植并发症工作组(TCWP)和儿科疾病工作组(PDWP)的回顾性调查

2026-07-270
PRE
Peri-Transplant Ruxolitinib Prophylaxis Improves Outcome in Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

移植前后鲁索利替尼预防可改善接受骨髓纤维化异基因造血细胞移植患者的预后

2026-07-220
OAAI
Rituximab, dexamethasone, etoposide, ifosfamide and carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma: a retrospective multicentre clinical study

利妥昔单抗、地塞米松、依托泊苷、异环磷酰胺和卡铂(R-DeVIC)在复发或难治性中枢神经系统淋巴瘤中的应用:一项回顾性多中心临床研究

2026-05-010
OA
Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy

原发性纵隔B细胞淋巴瘤: upfront高剂量化疗联合自体干细胞移植可带来良好的长期预后,并可能避免放射治疗

2026-04-170
OAAI
Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

异基因造血干细胞移植后复发的AML患者的突变谱变化

2026-04-030
OAAI
TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in amulti-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

TET2突变不影响接受造血干细胞移植且处于首次缓解期的成人急性髓系白血病患者的预后:欧洲血液与骨髓移植学会全球委员会和急性白血病工作组的多中心回顾性分析显示,配型相合的同胞或无关供者移植与单倍型相合供者移植后的结果相似。

2025-12-010
OAAI
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT

异基因造血干细胞移植不同供者类型在初治难治性急性髓系白血病中的疗效:EBMT ALWP 报告

2025-11-210
PRE
Influence of daytime of allogeneic stem cell transplantation on incidence of acute graft vs. host disease: a retrospective analytical cohort study

异基因干细胞移植进行时间对急性移植物抗宿主病发生率的影响:一项回顾性分析队列研究

2025-08-020
OAAI
The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation

系统性炎症反应测量作为异基因造血细胞移植后结局的移植前风险因素的重要性

2025-07-290
OA
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition

CAR T细胞治疗原发性或继发性中枢神经系统淋巴瘤患者的疗效和安全性: 代表EBMT和GoCART联盟的研究

2025-05-210
OA
Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey

Teduglutide治疗难治性严重肠道急性移植物抗宿主病——一项多中心调查

2025-04-140
OA
Guiding clinical management of patients with CNS lymphomas by minimal-invasive detection of ctDNA in cerebrospinal fluid

通过在脑脊液中微创检测ctDNA来指导CNS淋巴瘤患者的临床管理

LEUKEMIA
IF13.4
2025-04-090
OA
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
LEUKEMIA
IF13.4
2024-07-230
OAAI
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients
2024-05-021
OAAI